Abstract: O-GalNAc glycans are important structures in cellular homeostasis. Their biosynthesis is initiated by members of the polypeptide GalNAc-transferase (ppGalNAc-T) enzyme family. Mutations in ppGalNAc-T3 isoform cause diseases (congenital disorders of glycosylation) in humans. The K626 residue located in the C-terminal β-trefoil fold of ppGalNAc-T3 was predicted to be a site with high likelihood of acetylation by CBP/p300 acetyltransferase. We used a site-directed mutagenesis approach to evaluate the role of this acetylation site in biological properties of the enzyme. Two K626 mutants of ppGalNAc-T3 (T3  K626Q and T3   K626A ) had GalNAc-T activities lower than that of wild-type enzyme. Direct and competitive interaction assays revealed that GalNAc recognition by the lectin domain was altered in the mutants. The presence of GlcNAc glycosides affected the interaction of the three enzymes with mucin-derived peptides. In GalNAc-T activity assays, the presence of GlcNAc glycosides significantly inhibited activity of the mutant (T3 K626Q ) that mimicked acetylation. Our findings, taken together, reveal the crucial role of the K626 residue in the C-terminal β-trefoil fold in biological properties of human ppGalNAc-T3. We propose that acetylated residues on ppGalNAc-T3 function as control points for enzyme activity, and high level of GlcNAc glycosides promote a synergistic regulatory mechanism, leading to a metabolically disordered state.
Introduction
O-GalNAc glycans are abundant biopolymers in eukaryotic cells, and play important roles in cell-cell and cell-matrix adhesion, protein stability, and protease resistance (Brockhausen et al., 2009) . O-GalNAc glycans are aberrantly synthesized by epithelial tumor cells as a consequence of modified enzyme activity of glycosyltransferases (Kumar et al., 2005; Brockhausen, 2006) . In metastasis, truncated O-GalNAc glycans play a key role in adhesion of cancer cells to endothelial cells (Yu et al., 2007) . O-GalNAc glycan biosynthesis is initiated by members of the polypeptide GalNAc-transferase (ppGalNAc-T) enzyme family, which promote covalent linkage of GalNAc to serine/threonine (Ser/Thr) of an acceptor protein. This multi-gene family includes 20 ppGalNAc-T members in humans. The various isoforms are differentially expressed in mammalian cells and tissues during development and differentiation . The case of ppGalNAcT3 is an example of physiological importance without redundancy in ppGalNAc-Ts. Mutations in this isoform are responsible for human congenital disorders of glycosylation such as familial tumoral calcinosis (FTC) (Topaz et al., 2004) and hyperostosis hyperphosphatemia syndrome (HHS) (Duncan et al., 2011; Esapa et al., 2012) .
Changes in the expression of ppGalNAcT-s lead to alterations in O-GalNAc glycosylation. Altered expression patterns of these enzymes are often observed in cancer (Pinho and Reis, 2015) . ppGalNAc-T3 has been reported to be overexpressed in multiple cancers, predicting high tumor grade, shorter survival, or recurrence. Conversely, strong ppGalNAc-T3 expression was correlated with good prognosis in human colorectal carcinomas and non-small cell lung cancer; and in a mouse colon cancer model, loss of expression was associated with higher metastatic potential (Chia et al., 2016) .
ppGalNAc-Ts are type II transmembrane proteins in which the Golgi lumenal region comprises a stem section, catalytic domain, and C-terminal domain. The C-terminal domain has three QXW (Q = glutamine; W = tryptophan) sequence motifs characteristic of β-trefoil folds, similar to that of the Gal-binding B chain of ricin (Hazes and Read, 1995) . This motif, essentially a flexible lectin scaffold characteristic of the R-type lectin family, is present in the C-terminal domain of all ppGalNAc-Ts (Imberty et al., 1997) . Lectins are glycan-binding proteins important in mammalian cellular homeostasis . Numerous studies from the late 1980s (Barondes, 1988) to the present (Nagae and Yamaguchi, 2015) have revealed new lectins with multifunctional properties. Some of these lectins have a glycan-binding site and a pocket involved in protein-protein interaction.
The ε-amino group of lysine (Lys; K) is a highly reactive target site of many important protein post-translational modifications (PTMs), including acetylation, sumoylation, and ubiquitination (Yang and Seto, 2008) . Acetylation, the most evolutionarily conserved PTM, is ubiquitous in animal cells and mediates a wide variety of cellular and molecular processes, including chromatin remodeling, transcriptional regulation, cell cycle, splicing, nuclear transport, protein stability, intracellular localization, protein-protein interaction, and enzyme activity (Choudhary et al., 2009 , Drazic et al., 2016 . Lysine acetyltransferases and deacetylases, respectively, control incorporation and removal of acetyl residues from the Lys ε-amino group; i.e. acetylation is a reversible PTM.
Several enzymes involved in nucleotide sugar biosynthesis or other key glycobiological processes, including glycosyltransferases, glycosidases, and lectins, have been shown to be acetylated (Lundby et al., 2012; Pehar et al., 2012) . Among ppGalNAc-T family members, ppGalNAc-T2 and -T9 isoforms, are acetylated. Lysine acetylation is emerging as a major regulatory mechanism of metabolic enzymes and is altered frequently in human diseases (Xiong and Guan, 2012) .
In the present study, we used a site-directed mutagenesis approach to investigate the role of an acetylation site located in the β-trefoil fold of ppGalNAc-T3 in determining catalytic and binding properties.
Results

QKW acetylation site of ppGalNAc-T3
To identify acetylation sites on ppGalNAc-T3, we used the ASEB (Acetylation Set Enriched Based) online software program Wang et al., 2012) . The K626 residue had high likelihood (p = 0.0004) of acetylation by CBP/p300 acetyltransferase ( Figure 1A ). K626 is located in one of the QXW motifs of the lectin domain in which X = K ( Figure 1B) . The β-trefoil fold in the C-terminal region of ppGalNAc-Ts has three QXW motifs that are highly conserved among R-type lectin family members. The lectin domain of ppGalNAc-T2 also has a QKW sequence, in which K is acetylated (Zlocowski et al., 2011) .
The site-directed mutagenesis approach is widely used to mimic acetylation of specific K residues. In this approach, K is replaced by (i) glutamine (Q), which resembles acetylated K in terms of charge and structure, (ii) arginine (R), to prevent acetylation but conserve positive charge, or (iii) alanine (A), a neutral nonacetylated form (Costantini et al., 2007; Mak et al., 2014; DePaolo et al., 2016 Figure 1 ).
Role of K626 acetylation site in ppGalNAc-T3 enzyme activity
To evaluate the role of acetylation of the K626 residue in determining ppGalNAc-T3 enzyme activity, we measured GalNAc-T activity of an acetylation mimic mutant (T3 K626Q ). Catalytic activities of WT and single-point ppGalNAc-T3 mutants were analyzed using UDPαGalNAc as sugar donor and mucin-derived peptides as acceptors. Enzyme kinetics of GalNAc-Ts was evaluated by colorimetric assay, and data were fitted using a nonlinear regression algorithm. T3
K626Q displayed a significant reduction of GalNAc-T activity, relative to WT ppGalNAc-T3, when either MUC1 or MUC2 was used as acceptor substrate (Figure 2A,B) .
GalNAc-T activity of T3
K626A was also lower than that of WT. T3 K626R showed poor stability in solution; it was therefore not possible to evaluate its GalNAc-T activity. Kinetic parameters V max (maximal velocity) 
Role of K626 in lectin domain on interactions with glycans
Effects of K626 point mutations on interaction ability of ppGalNAc-T3 were studied using binding assays. In view of previous reports that the ppGalNAc-T3 lectin domain recognizes mainly GalNAc residues (Pedersen et al., 2011; Yoshimura et al., 2012) , we evaluated the role of K626 of ppGalNAc-T3 in GalNAc recognition. Direct binding assays showed that the MUC1αGalNAc-binding ability of T3 K626Q and T3
K626A was lower than that of WT ( Figure 3 ). To study the effects of carbohydrates and their derivatives on interaction of the three ppGalNAc-T3s with MUC1αGalNAc, the enzymes were incubated with MUC1αGalNAc under optimal interaction conditions in the presence of various concentrations of carbohydrates (Glc, GalNAc), GalNAc glycosides (BzlαGalNAc, pNPαGalNAc, pNPβGalNAc), and GlcNAc glycosides (MeαGlcNAc, MeβGlcNAc, UDPαGlcNAc). Glc and GalNAc had no significant effect on the binding of ppGalNAc-T3s to MUC1αGalNAc (Figure 4 ). GalNAc glycosides had a clear inhibitory effect on the binding of WT and T3 K626Q (IC50 ~10 mm) but not of T3 K626A (Figure 4 ; Supplementary Table 2 ). These findings indicate an important role of K626 in interaction of ppGalNAc-T3 lectin domain with terminal αGalNAc residues of glycopeptides.
GlcNAc glycosides had an interesting effect on interaction of WT and T3
K626Q enzymes with O-GalNAc glycopeptide. MeαGlcNAc and MeβGlcNAc enhanced the binding of both these enzymes to MUC1αGalNAc ( Figure  4 ; Supplementary Table 3), but had no effect on binding of T3 K626A enzyme. Thus, the binding abilities of ppGalNAc-T3 were altered by changes in K626. Various concentrations of T3 (black), T3 K626A (red), and T3 K626Q (blue) were incubated with MUC1αGalNAc. ppGalNAc-T3s were detected using anti-ppGalNAc-T3 and HRP-labeled secondary antibodies. Data shown are means from replicate experiments.
Effects of glycosides on interactions of three ppGalNAc-T3s with peptides MUC1 and MUC2
We incubated the three enzymes (ppGalNAc-T3s) with MUC1 under optimal interaction conditions in the presence of various concentrations of glycosides BzlαGalNAc and MeαGlcNAc. Both glycosides enhanced MUC1 binding of all three enzymes (interaction percentage >100%) in a concentration-dependent manner ( Figure 5A-C) . The two glycosides did not differ notably in their effects on WT or T3 K626A binding, whereas T3 K626Q binding was enhanced more strongly by BzlαGalNAc than by MeαGlcNAc (Supplementary Table 4 ).
The two glycosides also promoted binding of all three enzymes to MUC2 (Figure 5D-F) . In this case, the enhancing effect of MeαGlcNAc was stronger than that of BzlαGalNAc for T3 K626Q and T3 K626A binding, but the effects of the two glycosides did not differ notably for WT binding (Supplementary Table 5 ). Thus, glycosides differ in their effects on interactions of ppGalNAc-T3s with peptides.
Effects of GlcNAc glycosides on GalNAc-T activity of ppGalNAc-T3s
In view of the finding (above) that both BzlαGalNAc and MeαGlcNAc enhanced binding of ppGalNAc-T3s to mucin peptides, we examined the effects of GlcNAc glycosides on GalNAc-T activity of ppGalNAc-T3s, with emphasis on the acetylation mimic mutant (T3 K626Q ). In the catalytic reaction of WT ppGalNAc-T3 using UDPαGalNAc as donor substrate and MUC2 as acceptor peptide, the presence of GlcNAc glycosides had no important effect on kinetic parameters ( Figure 6A ). However, MeαGlcNAc and UDPαGlcNAc had notable inhibitory effects on GalNAc-T activity of T3 K626Q ( Figure 6B ). Kinetic parameters in these cases were calculated using the GraphPad Prism 5 software program, and K m and V max values are shown in Supplementary Table 6 . Double reciprocal plots of enzyme activity were constructed to assess the type of inhibitory effect on ppGalNAc-Ts. According to these plots, GlcNAc glycosides were not relevant inhibitors of WT enzyme activity ( Figure 6C ), whereas MeαGlcNAc was a competitive inhibitor and UDPαGlcNAc was a mixed inhibitor of T3 K626Q enzyme activity ( Figure 6D ).
Discussion
Human ppGalNAc-Ts are differentially expressed in various cell and tissues. Some ppGalNAc-Ts (e.g. ppGalNAc-T1, -T2, -T7) are ubiquitously expressed in organs, while others (e.g. ppGalNAc-T3, -T4, -T5, -T8, -T10, -T15) have restricted expression patterns . The large number of ppGalNAc-Ts involved in control of the initiation step of O-GalNAc glycosylation presumably provides substantial redundancy (back-up capability); i.e. loss of a single GALNT gene may not produce a discernible change of phenotype. However, mutations of a particular human GALNT gene, GALNT3, have been associated with autosomal recessive metabolic disorders (FTC, HHS) characterized by deregulation of phosphate homeostasis (Esapa et al., 2012) . ppGalNAc-T3 selectively glycosylates a furin-like convertase recognition sequence in fibroblast growth factor 23 (FGF23), a key regulator of phosphate pathway, thus averting proteolytic cleavage and allowing secretion of intact FGF23 (Kato et al., 2006) . The orthologous mouse gene, galnt3, evidently has similar functions. A mouse mutant homozygous for galnt3 with a Trp589Arg lectin domain mutation displayed a FTC-like phenotype (Esapa et al., 2012) . In the present study, we examined the role of an acetylation site in the lectin domain of human ppGalNAc-T3 in determining biological properties of the enzyme.
ppGalNAc-T3 mutants prepared by site-directed mutagenesis at residue K626 showed GalNAc-T activity lower than that of WT. This was true for two mutants (T3  K626Q and T3   K626A ), using two acceptor peptides (MUC1 and MUC2). V max was the most affected kinetic parameter. These findings illustrate the intrinsic effect of the lectin domain on catalytic activity of its own enzyme. Similar results were obtained for other ppGalNAc-Ts using a different approach (Revoredo et al., 2016) . We previously showed that GalNAc-T activity of ppGalNAc-T2 was reduced by K521Q mutation in a QKW motif of the lectin domain (Zlocowski et al., 2013) . K acetylation similarly inhibited catalytic activity of most metabolic enzymes (Xiong and Guan, 2012) .
We performed direct interaction assays between ppGalNAc-T3 and MUC1αGalNAc to evaluate the effect of PTM site at residue K626 on binding properties of the lectin domain. Binding of mutants to MUC1αGalNAc was lower than that of WT. In competitive interaction assays, mutations in lectin γ-subdomain of ppGalNAc-T3 yielded different results. The presence of GalNAc glycosides had no effect on T3 K626A binding to MUC1αGalNAc. . These findings demonstrate that K626 mutation alters GalNAc recognition by the ppGalNAc-T3 lectin domain, and indicate the importance of this site in this enzyme, and the effect of PTMs of the site on carbohydrate recognition. We showed previously that αGalNAc recognition by ppGalNAc-T2 was enhanced by K521Q mutation in the β-subdomain of the lectin domain (Zlocowski et al., 2013) .
Various glycosides affected interaction of ppGalNAcT3s with glycopeptides and peptides. Interaction of WT with MUC1αGalNAc was enhanced by GlcNAc glycosides. The enhancing effect of MeβGlcNAc was 3.3-fold higher (EC200:10/3) than that of MeαGlcNAc (Supplementary Table 3 ). Differential effects of the above GlcNAc glycosides on T3 K626Q interactions were less pronounced. The glycosides had no effect on T3 K626A interaction with MUC1αGalNAc.
Glycosides also enhanced binding of ppGalNAc-T3s to peptides. We observed for the first time that interaction of the enzymes with MUC1 or MUC2 was increased in the presence of GalNAc or GlcNAc glycosides. The soluble glycoside may be positioned in a 'carbohydrate-recognition pocket' in the lectin domain, thus promoting protein-protein interaction between enzyme and peptide. BzlαGalNAc preferentially enhanced binding of T3 K626Q to MUC1, while MeαGlcNAc enhanced binding to MUC2. Thus, protein-protein interaction of T3 K626Q , the mutant that mimics acetylation, is differentially affected by GalNAc vs. GlcNAc glycosides.
In view of the finding that glycosides enhanced interaction of ppGalNAc-T3s with acceptor peptides, we examined the effect of GlcNAc glycosides on GalNAc-T activity of the enzymes. MeαGlcNAc and UDPαGlcNAc had no notable effect on activity of WT enzyme, despite their enhancing effect on interaction with acceptor peptides. Both these glycosides inhibited GalNAc-T activity of T3
K626Q
. Thus, UDPαGlcNAc and other GlcNAc glycosides exert regulatory effects on enzyme activity of acetylated ppGalNAc-T3. Topaz et al. (2004) study showed that the severe autosomal recessive metabolic disorder FTC results from loss of exon 7, which encodes a fragment of ppGalNAc-T3's lectin domain. It is noteworthy that the deletion causing FTC occurred in the lectin α-subdomain sequence, rather than the catalytic domain. A later study showed that hyperostosis hyperphosphatemia syndrome (HHS) resulted from homozygous mutation W589R in the lectin domain of mouse GALNT3 (Esapa et al., 2012) . Residue W589 is part of the QXW motif in the lectin β-subdomain of ppGalNAc-T3. The fact that the W589R mutation by itself causes HHS demonstrates the essential role of this motif in protein function. Our previous studies have shown that mutations in the QKW motif (lectin γ-subdomain) of GALNT3 yield proteins (K626Q and K626A) having GalNAc-T activity much lower than that of WT. These mutations affect carbohydrate-recognition capacity of the lectin domain, as well as protein-protein interaction of β-trefoil fold, modulated by glycosides. These findings, taken together, reflect the crucial role of the lectin domain in biological properties of human ppGalNAc-T3.
We described for the first time extrinsic functions of the lectin domain of ppGalNAc-T3 and -T4, which modulate catalytic activity of glycosyltransferases localized in Golgi (Lorenz et al., 2016) . Results of the present study show that a PTM at K626 of ppGalNAc-T3 lectin domain and the presence of GlcNAc glycosides both induce changes in the lectin domain's interaction abilities and the enzyme's catalytic properties. The lectin domain of ppGalNAc-Ts is a member of the β-trefoil fold superfamily, characterized by high plasticity in regard to interacting structures (carbohydrates, proteins, DNA) (Azarkan et al., 2011) . The β-trefoil fold provides a favorable scaffold for interaction of ppGalNAc-T3 with carbohydrates or peptides.
We propose that under conditions that favor Lys acetylation, (i) acetylated residues on ppGalNAc-T isoforms function as control points for enzyme activity, and (ii) high levels of GlcNAc glycosides promote a synergistic regulatory mechanism of ppGalNAc-Ts leading to a metabolically disordered state.
Materials and methods
Prediction of acetylation sites on ppGalNAc-T3
Lys acetylation is an important factor in modeling of protein functions. In silico prediction of specific acetylation sites is often helpful in formulating experimental designs. We used the ASEB (Acetylation Set Enriched Based) online software program (http://bioinfo.bjmu.edu. cn/huac/) Wang et al., 2012) to predict Lys acetylation sites on human ppGalNAc-T3 by CBP/p300 acetyltransferases. ASEB predicted the top 3% acetylation sites as K126 (p = 0.0001) and K129 (p = 0.0043) in stem region, and K626 (p = 0.0004) in lectin domain.
Expression of ppGalNAc-T3 and single-point mutants
cDNAs of soluble enzymes were cloned into baculovirus expression vector pAcGP67 as described previously (Bennett et al., 1996) . Constructs were inserted into pAcGP67-His downstream containing a 6 × His-tag, generating pAcGP67-His-protein expression vectors. A Quick Change Kit (Stratagene, Germany) was used to generate the ppGalNAc-T3 mutants ppGalNAc-T3  K626Q (T3  K626Q ), ppGalNAc-T3   K626R (T3  K626R ), and ppGalNAc-T3  K626A (T3   K626A   ) , using pAcGP67-ppGalNAc-T3 His-soluble expression construct as template. The primers used were: T3K626QF (5′CAT CAG ATC CAC TCC AAC AAT GGA TAC TTA  GCC AA′3), T3K626QR (5′TTG GCT AAG TAT CCA TTG TTG GAG  TGG ATC TGA TG′3), T3K626RF (5′CAT CAG ATC CAC TCC AAA GAT  GGA TAC TTA GCC AA′3), T3K626RR (5′TTG GCT AAG TAT CCA TCT  TTG GAG TGG ATC TGA TG′3), T3K626AF (5′CAT CAG ATC CAC TCC  AAG CAT GGA TAC TTA GCC AA′3) , and T3K626AR (5′TTG GCT AAG TAT CCA TGC TTG GAG TGG ATC TGA TG′3) (TAG Copenhagen A/S, Denmark). Sf9 insect cells were grown at 27°C in Grace's insect medium containing 10% FCS. pAcGP67-His-protein plasmids were co-transfected with BaculoGold DNA (BD Biosciences). Recombinant baculovirus were obtained after two successive amplifications in Sf9 cells grown in serum-containing medium. Virus titers were estimated by titration in 24-well plates and monitoring of enzyme activity.
Protein purification
Secreted, soluble recombinant proteins were purified from supernatant of Sf9 cell culture medium after centrifugation at 1500 rpm for 15 min at 4°C. The supernatant was dialyzed (membrane MWCO <10 kDa) against PBS (10 mm sodium phosphate, pH 7.4, 150 mm NaCl), and re-centrifuged at 200 g for 30 min at 4°C. Proteins were purified using HisPur™ Cobalt Resin (Thermo Scientific) and eluted with 150 mm imidazole (Zlocowski et al., 2013) . Eluted proteins were dialyzed three times against PBS and concentrated by a centrifuge filter device (Millipore; MWCO <10 kDa). Total protein content was measured by bicinchoninic acid assay with BSA as standard (Pierce; Thermo Scientific). Homogeneity of recombinant proteins was confirmed by SDS-PAGE and Coomassie Brilliant Blue staining.
GalNAc-T assay
Polystyrene microtiter plates (Corning, Costar) were coated with 50 μl MUC2 33 (PTTTPITTTTTVTPTPTPTGTQTPTTTPISTTC) or MUC1 60 (TAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHG-VTSAPDTRPAPGS) peptide in carbonate buffer (pH 9.6) overnight at 4°C, washed with PBS, and blocked with 0.1% Tween 20 in PBS for 1 h at RT. The catalytic reaction mixture contained 25 mm cacodylate (pH 7.4), 10 mm MnCl 2 , 0.05% Tween 20, 0.5 μg/ml ppGalNAc-T3s, and 50 μm UDPαGalNAc. Enzymatic reaction mixture was incubated 15 min at 37°C, washed with PBS, incubated 60 min at RT with HRP-HPA diluted 1/1000 in PBS with 0.05% Tween 20, and washed with PBS. Color was developed with 0.5 mg/ml o-phenylenediamine and 0.02% H 2 O 2 in sodium citrate (pH 5.0) at RT, and reaction was stopped by addition of 0.5 N H 2 SO 4 , 50 μl/well. Absorbance was recorded by microplate reader at 490 nm (Lorenz et al., 2016) . Nonlinear fitting of curves and enzyme kinetic parameters were obtained using the GraphPad Prism 5 software program.
Effects of GlcNAc glycosides on GalNAc-T activity
Microtiter plates were coated with 50 μl MUC2 33 (1 μg/ml) peptide in carbonate buffer (pH 9.6) overnight at 4°C, washed with PBS, and blocked with 0.1% Tween 20 in PBS for 1 h at RT. The catalytic reaction mixture contained 25 mm cacodylate (pH 7.4), 10 mm MnCl 2 , 0.05% Tween 20, 0.5 μg/ml ppGalNAc-T3s, and UDPαGalNAc (4-512 μm), with or without addition of 200 μm UDPαGlcNAc or MeαGlcNAc. Enzymatic reaction mixture was incubated 15 min at 37°C and processed as described in the preceding section.
Binding assay
Microtiter plates were coated with peptide MUC2 33 , peptide MUC1 60 , or glycopeptide MUC1 60 αGalNAc 15 (MUC1αGalNAc) in carbonate buffer (pH 9.6) overnight at 4°C, washed with PBS, blocked with 0.1% Tween 20 in PBS for 1 h at RT, and washed with PBS. Various concentrations of WT ppGalNAc-T3 and its mutants T3 K626Q and T3
K626A were added to the plates, incubated 2 h at RT, washed with PBS, incubated 60 min at RT with rabbit anti-ppGalNAc-T3 antibody (Sigma-Aldrich, St. Louis, USA) in PBS with 0.05% Tween 20, and washed with PBS. Wells were added with HRP-labeled goat antirabbit IgG antibody in PBS with 0.05% Tween 20, incubated 60 min at RT, and washed with PBS as described previously (Lorenz et al., 2016) . Color was developed and absorbance recorded as described under 'GalNAc-T assay'.
Binding assay in presence of carbohydrates
This procedure was the same as described above, except that the three enzymes (ppGalNAc-T3, T3  K626Q , T3   K626A ) (each 1 μg/ml) were preincubated with various concentrations of carbohydrates for 1 h at RT and then added to wells.
